JTD专栏 JTD Column

挑战肺栓塞——新一代口服抗凝血剂

Published at: 2013年第33卷第3期

Sérgio Barra 1 , Luís Paiva 1 , Rui Providência 1
1 Cardiology Department, Coimbra University and Hospital Centre, Coimbra, Portugal
通讯作者 Barra Sérgio Email: sergioncbarra@gmail.com
DOI: 10.3978/j.issn.2095-6959.10.3978/j.issn.2095-6959.2013.03.004
基金:

摘要

急性肺栓塞(pulmonary embolism,PE)是一种较常见的心血管急症,每年的发病率约为70/10万[1]。肺动脉血管床堵塞可能危及生命且存在可逆急性右心衰竭风险,这一点突出了早期准确诊断的必要性。初始治疗的主要目标是恢复堵塞的肺动脉血流并预防早期复发。

关键词: 急性肺栓塞

Challenging pulmonary embolism - A new generation of oral anticoagulants

Abstract

Acute pulmonary embolism (PE) is a relatively common cardiovascular emergency, with an estimated annual incidence of 70 cases per 100,000 individuals (1). Occlusion of the pulmonary arterial bed may lead to acute life-threatening but potentially reversible right ventricular failure, highlighting the need for an early and accurate diagnosis. Initial therapy aims primarily at restoration of flow through occluded pulmonary arteries and the prevention of early recurrences.

Keywords: pulmonary embolism

comments powered by Disqus

全文

引用

引用本文: Barra Sérgio , Paiva Luís, Providência Rui . 挑战肺栓塞——新一代口服抗凝血剂[J]. 临床与病理杂志, 2013, 33(3): 202-204.
Cite this article as: S RGIO Barra, LU S Paiva, RUI Providncia . Challenging pulmonary embolism - A new generation of oral anticoagulants[J]. Journal of Clinical and Pathological Research, 2013, 33(3): 202-204.